F741 KAIST-ICC, 193 Munji-ro
We are a Global New Drug Development Company. have EC-18, our leading compound to treat chemotherapy-induced neutropenia and thrombocytopenia. EC-18 is non-protein small molecule oral first-in-class drug as supplemental for most cancer drugs. We ...
D-Cycloserine,Terizidone,Erdosteine,Cefotiam,Cefazedone